Skip to content

    Rossari Biotech Limited

    Specialty chemicals maker for home & personal care, textiles and animal health, built via Unitop and Tristar acquisitions.

    Chemicals
    Commodities
    View ROSSARI earnings calls
    ₹560.9
    +11.22% from avg

    Overview

    Price

    ₹560.9

    Market Cap

    ₹2.7k Cr

    Sector

    Chemicals

    Commodities

    Rank

    5

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital1010111111111111
    Reserves2773987949041.0k1.2k1.2k1.3k
    Borrowings670874119218353436
    Other Liabilities118152442375401482484505
    Total Liabilities4715611.3k1.4k1.6k1.9k2.1k2.3k
    AssetsFixed Assets94181607585578598630784
    CWIP22011647140247173
    Investments180365163842062
    Other Assets3383796117128801.1k1.2k1.3k
    Total Assets4715611.3k1.4k1.6k1.9k2.1k2.3k

    Valuation

    Assumptions

    Current — ROSSARI
    Price
    ₹561
    EPS (TTM)
    ₹23.25
    PE (TTM)
    24.1
    Profit growth
    6.6%

    The Earnings Per Share over the last 12 months.

    %

    Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).

    Pre-filled with the lower of median (29.9×) and current (24.1×) PE — the conservative anchor.

    %

    The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.

    Valuation

    Current price
    ₹561
    vs
    Fair value · 15% return
    ₹325
    42%Overvalued

    At 6.6% growth and a 24× exit, ₹561 only delivers your return if you pay ₹325. The price is currently baking in 18% growth.

    EPS grows 6.6%/yr for 5 years, then fades to 6% over 2, exits at 24×.

    YearGrowthEPS (₹)
    FY276.6%24.78
    FY286.6%26.42
    FY296.6%28.16
    FY306.6%30.02
    FY316.6%32.00
    FY326.3% ·fade34.02
    FY336.0% ·fade36.06

    Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.

    Learn to analyse Rossari Biotech Limited

    Guides on how to read this kind of business and the numbers that matter.